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Abstract
Many aspects of the complex interaction between HIV and the human
immune system remain elusive. Our objective is to study these inter-
actions, focusing on the specific roles of langerhans cells (LCs) in HIV
infection. In patients infected with HIV, a large amount of virus is as-
sociated with LCs in lymphoid tissue. To assess the influence of LCs on
HIV viral dynamics during anti-retroviral therapy, we present and anal-
yse a stochastic model describing the dynamics of HIV, CD4+ T-cells,
and LCs interactions under therapeutic intervention in vivo. We per-
form sensitivity analyses on the model to determine which parameters
and/or which interaction mechanisms strongly affect infection dynam-
ics.
Keywords: HIV infection, Latent period, Langerhans cells, CD4+ T cells,
Stochastic model, Therapeutic intervention.




HIV is a devastating human pathogen that causes serious immunological dis-
eases in humans around the world. The virus is able to remain latent in an
infected host for many years, allowing for the long-term survival of the virus
and inevitably prolonging the infection process [3]. The location and mecha-
nisms of HIV latency are under investigation and remain important topics in
the study of viral pathogenesis. Given that HIV is a blood-borne pathogen,
a number of cell types have been proposed to be the sites of latency, includ-
ing resting memory CD4 + T cells, peripheral blood monocytes, dendritic
cells (including langerhans cells) and macrophages in the lymph nodes, and
haematopoietic stem cells in the bone marrow [16]. This study updates the
latest advances in the study of HIV interactions with langerhans cells, and
highlights the potential role of these cells as viral reservoirs and the effects of
the HIV-host-cell interactions on viral pathogenesis.
Despite advances in our understanding of HIV and the human immune re-
sponse in the last 25 years, much of this complex interaction remains elusive.
CD4+ T-cells are targets of HIV, and are also important for the establishment
and maintenance of an adaptive immune response [7]. The skin and mucosa
are the first line of defense of the organism against external agents, not only as
a physical barrier between the body and the environment but also as the site
of initiation of immune reactions. The immunocompetent cells which act as
antigen-presenting cells are Langerhans cells (LCs). Infection of LCs by HIV
is relevant for several reasons. Firstly, LCs of mucosal epithelia may be among
the first cells to be infected following mucosal HIV exposure and Secondly, LCs
may serve as a reservoir for continued infection of CD4+ T cells, especially in
lymph nodes where epidermal LCs migrate following antigenic activation[11].
Many indirect and/or direct experimental data have shown that LCs may be
a privileged target, reservoir and vector of dissemination for the HIV from
the inoculation sites (mucosa) to lymph nodes where the emigrated infected
LCs could infect T lymphocytes [17]. Originated from the bone marrow, LCs
migrate to the peripheral epithelia (skin, mucous membranes) where they play
a primordial role in the induction of an immune response and are especially
active in stimulating naive T lymphocytes in the primary response through a
specific cooperation with CD4-positive lymphocytes after migration to proxi-
mal lymph nodes [15]. Apart from many plasma membrane determinants, LCs
also express CD4 molecules which make them susceptible targets and reser-
voirs for HIV [4]. Once infected, these cells due to their localization in areas
at risk (skin, mucous membranes), their capacity to migrate from the epider-
mal compartment to lymph nodes and their ability to support viral replication
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without major cytopathic effects, could play a role of vector in the dissemina-
tion of virus from the site of inoculation to the lymph nodes and thereby to
contribute to the infection of T lymphocytes [4].
Langerhans cells (LCs) which are members of the dendritic cells family and
are professional antigen-presenting cells, reside in epithelial surfaces such as
the skin and act as one of the primary, initial targets for HIV infection [14].
They specialize in antigen presentation and belong to the skin immune sys-
tem (SIS) and play a major role in HIV pathogenesis. As part of the normal
immune response, LCs capture virions at the site of transmission in the mu-
cosa(peripheral tissues), and migrate to the lymphoid tissue where they present
to naive T cells and hence are responsible for large-scale infection of CD4+
T lymphocytes [14]. These cells play an important role in the transmission of
HIV to CD4+ cells [6], thus, LC - CD4+ cell interactions in lymphoid tissue,
which are critical in the generation of immune responses, are also a major cat-
alyst for HIV replication and expansion. This replication independent mode of
HIV transmission, known as trans-infection, greatly increases T cell infection
in vitro and is thought to contribute to viral dissemination in vivo [10].
The Langerhans cell is named after Paul Langerhans, a German physician and
anatomist, who discovered the cells at the age of 21 in 1868 while he was
a medical student [13]. The uptake HIV by professional antigen presenting
cells (APCs) and subsequent transfer of virus to CD4+ T cells can result in
explosive levels of virus replication in the T cells. This could be a major
pathogenic process in HIV infection and development of AIDS. This process of
trans (Latin; to the other side) infection of virus going across from the APC to
the T cell is in contrast to direct, cis (Latin; on this side) infection of T cells
by HIV [12]. Langerhans cell results in a burst of virus replication in the T
cells that is much greater than that resulting from direct, cis infection of either
APC or T cells, or trans infection between T cells. This consequently shows
that Langerhans cells may be responsible for the quick spread of HIV infection.
The individual cells of the immune system are highly interactive, and the over-
all function of the system is a product of this multitude of interactions. The
interplay between HIV and the immune system is particularly complicated, as
HIV directly interacts with many immune cells, altering their functions, ulti-
mately subverting the system at its core [7]. Because of this complexity, the
immune response and its interaction with HIV are naturally suited to a math-
ematical modelling approach. Elucidating the mechanisms of LC-HIV-CD4+
T cells interactions is crucial in uncovering more details about host-HIV dy-
namics during HIV infection. To explore the role of LCs in HIV infection, we
first develop a stochastic model of HIV dynamics in vivo before therapy. Next,
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we introduce therapeutic intervention and finally investigate which parameters
and/or which interaction mechanisms strongly affect the infection dynamics.
The organization of this paper is as follows: In Section 2, we formulate our
stochastic model describing the interaction of HIV and the immune system
and obtain a partial differential equation for the joint probability generating
function of the numbers of healthy immune cells,the HIV infected immune
cells, and the free HIV particles at any time t. The marginal probability
distributions for the variables and the population measures which include the
expectation of the variables are also derived in Section 2. HIV dynamic model
incorporating therapy is derived and model analysis discussed in section 3.
Some concluding remarks follow in Section 4.
2 The role of LC in HIV Infection in Vivo
In HIV infection, LCs play a dual role of promoting immunity while also facili-
tating infection. During antigen presentation, LC-associated virus, migrate to
the lymphoid tissue where they present to naive T cells and hence facilitating
infection of CD4+ T-cells [1]. Taken together, these interactions suggest that
LC dynamics are particularly important to HIV infection. Several mechanisms
have been proposed to trigger progression from the chronic phase of infection
to AIDS. Many have hypothesized that progressive alteration of the immune
system results in the transition to AIDS [2],[5].
To study the roles of LCs during HIV infection, we present a mathematical
model of HIV infection and accompanying immune response. specifically, we
develop a stochastic model focusing on the HIV-LC-CD4+ cell dynamics in
Vivo. Our model analysis allows us to predict the importance of LC mech-
anisms and their role in triggering progression to AIDS. In particular, our
model predicts which mechanisms of LC dysfunction are most significant in
the transition to AIDS. A typical life-cycle of HIV virus and immune system
interaction is shown in Figure 1.
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Figure 1: The interaction of HIV virus and the immune system
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2.1 Variables and parameters for the model
The variables and parameters in the model are described as in tables 1 and 2:
Table 1: Variables for the Stochastic model
Variable Description
T (t) The concentration of healthy (susceptible)CD4+ cells at time t
TI(t) The concentration of infected CD4+ cells at time t
L(t) The concentration of healthy (susceptible) Langerhans cells at time t
LT (t) The concentration of latently infected Langerhans cells at time t
LI(t) The concentration of infected Langerhans cells at time t
V (t) The concentration of virus particles at time t
Table 2: Parameters for the stochastic model
Parameter Description
λT The total rate of production of healthy CD4+ cells per unit time
λL The total rate of production of Langerhans cells per unit time
δ The per capita death rate of healthy CD4+ cells
σ The per capita death rate of healthy Langerhans cells
β1 The transmission coefficient between uninfected CD4+ cells and
infective virus particles
β2 The transmission coefficient between uninfected CD4+ cells and
IV infected langerhans cells
β3 The transmission coefficient between uninfected langerhans cells and
infective virus particles
β4 The transmission coefficient between uninfected langerhans cells and
HIV infected langerhans cells
κ per capita death rate of infected CD4+ cells
τ Intracellular delay time
γ per capita death rate of infected langerhans cells
µ The per capita death rate of infective virus particles
N The average number of infective virus particles produced
by an infected CD4+ cell in the absence of treatment
during its entire infectious lifetime
M The average number of infective virus particles produced
by an infected langerhans cell in the absence of treatment
during its entire infectious lifetime
From the assumptions above and by using the population change scenarios and
parameters in tables 2 and applying probability arguments, we now summarize
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the events that occur during the interval (t, t+∆) together with their transition
probabilities in table 3.
Possible transitions in host interaction of HIV and Immune system Cells
and corresponding probabilities
Event Population components Population components probability
(T, TI , L, LI , V ) at t (T, TI , L, LI , V ) at (t, t+ ∆) of transition
Production of (x− 1, xI , y, yI , v) (x, xI , y, yI , v) λT∆t
healthy CD4+ cell
Death of (x+ 1, xI , y, yI , v) (x, xI , y, yI , v) δ(x+ 1)∆t
healthy CD4+ cell




Production of (x, xI , y − 1, yI , v) (x, xI , y, yI , v) λL∆t
Langerhans cell
Death of (x, xI , y + 1, yI , v) (x, xI , y, yI , v) σ(y + 1)∆t
Langerhans cell
Infection of (x, xI , y + 1, yI − 1, v + 1) (x, xI , y, yI , v) β3(y + 1)(v + 1)∆t
+β4(y + 1)(yI)∆t
Langerhans cell
Production of (x, xI + 1, y, yI + 1, v − 1) (x, xI , y, yI , v) κN(xI + 1)∆t+ γM(yI + 1)∆t
virons from the
infected cell
Death of virons (x, xI , y, yI , v + 1) (x, xI , y, yI , v) µ(v + 1)∆t
Table 3: In - Host interaction of HIV
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The change in population size during the time interval ∆t, which is assumed
to be sufficiently small to guarantee that only one such event can occur in
(t, t+ ∆t), is governed by the following conditional probabilities;
Px,xI ,y,yI ,v(t+ ∆t) = {1− (λT∆t+ λL∆t+ δx∆t+ σy∆t
+ β1xv∆t+ β2xyI∆t+ +β3yv∆t+ β4yyI∆t
+ κxI∆t+ γyI∆t+ µv∆t) + o(∆t)}Px,xI ,y,yI ,v(t)
+ {λT∆t+ o(∆t)}Px−1,xI ,y,yI ,v(t)
+ {λL∆t+ o(∆t)}Px,xI ,y−1,yI ,v(t) (1)
+ {δ(x+ 1)∆t+ o(∆t)}Px+1,xI ,y,yI ,v(t)
+ {σ(y + 1)∆t+ o(∆t)}Px,xI ,y+1,yI ,v(t)
+ {[β1(x+ 1)(v + 1) + β2(x+ 1)(yI)]e−ρτ∆t+ o(∆t)}Px+1,xI−1,y,yI ,v+1(t)
+ {[β3(y + 1)(v + 1) + β4(y + 1)(yI)]∆t+ o(∆t)}Px,xI ,y+1,yI−1,v+1(t)
+ {κN(xI + 1)∆t+ o(∆t)}Px,xI+1,y,yI ,v−1(t)
+ {γM(yI + 1)∆t+ o(∆t)}Px,xI ,y,yI+1,v−1(t)
+ {µ(v + 1)∆t+ o(∆t)}Px,xI ,y,yI ,v+1(t)
Re-arranging equation 1, then dividing through by ∆t, and taking the limit as
∆t⇒ 0 we have the following difference differential equation.
P ′x,xI ,y,yI ,v(t) = −{λT + λL + δx+ σy + β1xv + β2xyI
+ β3yv + β4yyI + κxI + γyI + µv}Px,xI ,y,yI ,v(t)
+ λTPx−1,xI ,y,yI ,v(t) + λLPx,xI ,y−1,yI ,v(t)
+ δ(x+ 1)Px+1,xI ,y,yI ,v(t) + σ(y + 1)Px,xI ,y+1,yI ,v(t)
+ {β1(x+ 1)(v + 1) + β2(x+ 1)(yI)}e−ρτPx+1,xI−1,y,yI ,v+1(t)
+ {β3(y + 1)(v + 1) + β4(y + 1)(yI)}Px,xI ,y+1,yI−1,v+1(t)
+ κN(xI + 1)Px,xI+1,y,yI ,v−1(t) + γM(yI + 1)Px,xI ,y,yI+1,v−1(t)
+ µ(v + 1)Px,xI ,y,yI ,v+1(t)
(2)
This is also called the Master equation or the Forward Kolmogorov Partial
differential equation for Px,xI ,y,yI ,v(t), with initial condition
P ′0,0,0,0,0(t) = −(λT + λL)P0,0,0,0,0(t) + δP1,0,0,0,0(t) + σP0,0,1,0,0(t) + µP0,0,0,0,1(t)
For detailed description and derivation of the model we refer the reader to [9]
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2.2 The Probability Generating Function









5 and summing over x, y, xI , yI and v, then applying the properties
of generating function, we obtain
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On simplification we have,
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+ β3(z4 − z2z5)
∂2G
∂z2∂z5
+ β4(z4 − z2z4)
∂2G
∂z2∂z4
This is called Lagrange partial differential equation for the probability gener-
ating function (pgf)
2.3 The marginal generating functions
Recall that










Assuming z2 = z3 = z4 = z5 = 1 and solving equation 3, we obtain the
marginal partial generating function for Healthy CD4+ cells.
∂G(z1, 1, 1, 1, 1; t)
∂t












Assuming z1 = z3 = z4 = z5 = 1 and solving equation 3, we obtain the
marginal partial generating function for Healthy Langerhans cells.
∂G(1, z2, 1, 1, 1; t)
∂t









Assuming z1 = z2 = z4 = z5 = 1 and solving equation 3, we obtain the
marginal partial generating function for Infected CD4+ cells.
∂G(1, 1, z3, 1, 1; t)
∂t








−ρτ − 1) ∂
2G
∂z1∂z4
Assuming z1 = z2 = z3 = z5 = 1 and solving equation 3, we obtain the
marginal partial generating function for Infected Langerhans cells.
∂G(1, 1, 1, z4, 1; t)
∂t
= (M − z4)γ
∂G
∂z4
+ β3(z4 − 1)
∂2G
∂z2∂z5
Assuming z1 = z2 = z3 = z4 = 1 and solving equation 3, we obtain the
marginal partial generating function for virus population.
∂G(1, 1, 1, 1, z5; t)
∂t
= (Nz5 − 1)κ
∂G
∂z3













2.4 Numbers of Cells and the Virons

















Differentiating the partial differential equation of the pgf, we get the moments
of T (t), L(t), TI(t), LI(t) and V (t).
Differentiating equation 3 with respect to z1, and setting z=1, we have
∂
∂t
E[T (t)] = λT − δE[T (t)]− β1E[T (t)V (t)]− β2E[T (t)LI(t)]
Differentiating equation 3 with respect to z2, and setting z = 1, we have
∂
∂t
E[L(t)] = λL − σE[L(t)]− β3E[L(t)V (t)]− β4E[L(t)LI(t)]
Differentiating equation 3 with respect to z3, and setting z = 1, we have
∂
∂t
E[TI(t)] = −κE[TI(t)] + β1e−ρτE[T (t)V (t)] + β2e−ρτE[T (t)LI(t)]
Differentiating equation 3 with respect to z4, and setting z = 1, we have
∂
∂t
E[LI(t)] = −γE[LI(t)] + β3E[L(t)V (t)]
Differentiating equation 3 with respect to z5, and setting z = 1, we have
∂
∂t
E[V (t)] = NκE[TI(t)] +MγE[LI(t)]− µE[V (t)]− β1E[T (t)V (t)]− β3E[L(t)V (t)]
Therefore the moments of T (t), L(t), TI(t), LI(t) and V (t) from the pgf before
introduction of treatment are
∂
∂t
E[T (t)] = λT − δE[T (t)]− β1E[T (t)V (t)]− β2E[T (t)LI(t)]
∂
∂t
E[L(t)] = λL − σE[L(t)]− β3E[L(t)V (t)]− β4E[L(t)LI(t)]
∂
∂t
E[TI(t)] = −κE[TI(t)] + β1e−ρτE[T (t)V (t)] + β2e−ρτE[T (t)LI(t)]
∂
∂t
E[LI(t)] = −γE[LI(t)] + β3E[L(t)V (t)] (4)
∂
∂t
E[V (t)] = NκE[TI(t)] +MγE[LI(t)]− µE[V (t)]− β1E[T (t)V (t)]− β3E[L(t)V (t)]
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3 HIV dynamics under Therapeutic interven-
tion
Introducing the effect of treatment, we have the following forward Kolmogorov
partial differential equations (Master equation) for Px,xI ,y,yI ,v(t)
P ′x,xI ,y,yI ,v(t) = −{λT + λL + δx+ σy + (1− α)β1xv + (1− α)β2xyI + (1− α)β3yv + (1− α)β4yyI
+ (1− ω)κxI + (1− ω)γyI + µv}Px,xI ,y,yI ,v(t) + λTPx−1,xI ,y,yI ,v(t) + λLPx,xI ,y−1,yI ,v(t)
+ δ(x+ 1)Px+1,xI ,y,yI ,v(t) + σ(y + 1)Px,xI ,y+1,yI ,v(t)
+ {β1(x+ 1)(v + 1) + β2(x+ 1)(yI)}(1− α)e−ρτPx+1,xI−1,y,yI ,v+1(t)
+ {β3(y + 1)(v + 1) + β4(y + 1)(yI)}(1− α)Px,xI ,y+1,yI−1,v+1(t)
+ (1− ω)κN(xI + 1)Px,xI+1,y,yI ,v−1(t) + (1− ω)γM(yI + 1)Px,xI ,y,yI+1,v−1(t) (5)
+ µ(v + 1)Px,xI ,y,yI ,v+1(t)
With initial condition
P ′0,0,0,0,0(t) = −(λT + λL)P0,0,0,0,0(t) + δP1,0,0,0,0(t) + σP0,0,1,0,0(t) + µP0,0,0,0,1(t)
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∂z3






+ (1− α)β1(z3e−ρτ − z1z5)
∂2G
∂z1∂z5
+ (1− α)β2(z3e−ρτ − z1z4)
∂2G
∂z1∂z4
+ (1− α)β3(z4 − z2z5)
∂2G
∂z2∂z5




Solving the pgf of the In-host HIV dynamics with therapeutic intervention, we
have the moments of T (t), L(t), TI(t), LI(t) and V (t).
∂
∂t
E[T (t)] = λT − δE[T (t)]− (1− α)β1E[T (t)V (t)]− (1− α)β2E[T (t)LI(t)]
∂
∂t
E[L(t)] = λL − σE[L(t)]− (1− α)β3E[L(t)V (t)]− (1− α)β4E[L(t)LI(t)]
∂
∂t




E[LI(t)] = −γE[LI(t)] + (1− α)β3E[L(t)V (t)] (7)
∂
∂t
E[V (t)] = (1− ω)NκE[TI(t)] + (1− ω)MγE[LI(t)]− µE[V (t)]
− (1− α)β1E[T (t)V (t)]− (1− α)β3E[L(t)V (t)]
3.1 Simulation results
3.2 Variables and parameter values
The initial variable values and parameter values for the model are described
in tables 4 and 5 below:
Table 4: Variables for the Stochastic model
Variable Description Initial condition
T (t) The concentration of healthy (susceptible)CD4+ cells
at time t 100
TI(t) The concentration of infected CD4+ cells
at time t 0.02
L(t) The concentration of healthy (susceptible) Langerhans cells
at time t 200
LI(t) The concentration of infected Langerhans cells
at time t 0.1
V (t) The concentration of virus particles
at time t 0.001
Using the parameter values and initial conditions defined in Tables 4 and 5,
we illustrate the general dynamics of the CD4- T cells and HIV virus for by
performing sensitivity analysis on the effect of intracellular delay and drug
efficacy.
From the simulations, it is clear that in the primary stage of HIV infection,
drastic decrease in the levels of healthy immune cells occur but the number of
free virons and infected LCs increase with time, see figures 2 and 3.
With 60% drug efficacy, the virus population drops and stabilizes after some
time t, but the number of infected LCs increase with time, see figures 4 and 5.
An increase in efficacy for the current HIV drugs, a patient will have low,
undetectable viral load levels but the population of infected LCs is still at
large, see figures 6 and 7.
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Table 5: Parameters for the stochastic model
Parameter Parameter description Estimate
(1− α) The reverse transcriptase inhibitor
drug effect 0.5
(1− ω) The protease inhibitor drug effect 0.5
λT The total rate of production of healthy CD4+ cells per unit time 10
λL The total rate of production of Langerhans cells per unit time 10
δ The per capita death rate of healthy CD4+ cells 0.02
σ The per capita death rate of healthy Langerhans cells 0.001
β1 The transmission coefficient between uninfected CD4+ cells and
infective virus particles 0.24e-4
β2 The transmission coefficient between uninfected CD4+ cells
and HIV infected langerhans cells 0.04e-4
β3 The transmission coefficient between uninfected langerhans cells
and infective virus particles 0.45e-4
β4 The transmission coefficient between uninfected langerhans cells
and HIV infected langerhans cells 0.14e-4
κ per capita death rate of infected CD4+ cells 0.5
ρ The death rate of infected but not yet virus producing cell 0.5
τ Intracellular delay time 0.5
γ per capita death rate of infected langerhans cells 0.001
µ The per capita death rate of infective virus particles 3
N The average number of infective virus particles produced
by an infected CD4+ cell in the absence of treatment
during its entire infectious lifetime 1000
M The average number of infective virus particles produced
by an infected langerhans cell in the absence of treatment
during its entire infectious lifetime 500
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Figure 2: Cells and HIV population dynamics before therapeutic interven-
tion.Shows the population dynamics when τ = 0
Figure 3: Cells and HIV population dynamics before therapeutic interven-
tion.Shows the population dynamics when τ = 2
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Figure 4: Cells and HIV population dynamics under therapeutic interven-
tion.Shows the population dynamics with drug efficacy of 60% and when τ = 0
Figure 5: Cells and HIV population dynamics under therapeutic interven-
tion.Shows the population dynamics with drug efficacy of 60% and when τ = 2
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Figure 6: Cells and HIV population dynamics under therapeutic interven-
tion.Shows the population dynamics with drug efficacy of 85%
Figure 7: Cells and HIV population dynamics under therapeutic interven-
tion.Shows the population dynamics with drug eficacy of 85% and when τ = 1
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4 Discussion
In this study, we derived and analyse a stochastic model describing the dynam-
ics of HIV, CD4+ T-cells, and LCs interactions under therapeutic intervention
in vivo. This model included dynamics of five compartments- the number of
healthy CD4 cells, the number of infected CD4 cells, the number of healthy
langerhans cells, the number of infected langerhans cells and the HIV virons.
The model describes HIV infection before and during therapy. We derived
equations for the the joint probability generating function of the numbers of
healthy immune cells,the HIV infected immune cells, and the free HIV parti-
cles at any time t, and obtained the moment structures of the healthy immune
cells, infected immune cells and the virus particles over time t. We simulated
the mean number of the healthy immune cells, the infected immune cells and
the virus particles before and after combined therapeutic treatment at any
time t.
Our analysis show that eradication of HIV is not possible without clearance of
latently infected langerhans cells. Therefore, understanding HIV therapeutic
treatment dynamics in vivo is critical to eliminating the virus, which shows
that LCs are important in determining the disease progression. Our model
analysis suggest that, therapies should be developed to block the binding of
HIV onto langerhans cells. Such therapies will have the potential to dramati-
cally accelerate viral decay. We conclude that to control the concentrations of
the virus and the infected cells in HIV infected person, a strategy should aim
to improve the drug efficacy, hence the efficacy of the protease inhibitor and
the reverse transcriptase inhibitor and also the intracellular delay play crucial
role in preventing the progression of HIV [8]. These findings illustrates the
role of LCs as a central hub of interaction and information exchange during
HIV infection. Our model produces interesting feature that, classification of
HIV disease states should not be based on CD4+ cells as the only immune
cells infected by the virus. The most reliable HIV state classification criteria
should be the CDC/WHO classification.
In our work, the dynamics of mutant virus was not considered and also our
study only included dynamics of only five compartments (healthy immune cells,
infected immune cells and free virus particles- ignoring the latency of infected
immune cells) of which extensions are recommended for further extensive re-
search. In a follow-up work, we intend to obtain real data in order to test the
efficacy of our models as we have done here with simulated data.
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